{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:45Z","timestamp":1785822465784,"version":"3.56.0"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by releasing inhibitory pathways that restrain antitumor T-cell responses. Their success has renewed interest in checkpoint blockade for infectious diseases, particularly chronic viral infections, sepsis-associated immunosuppression, and refractory opportunistic infections. In these settings, immune checkpoints may contribute to pathogen persistence by limiting effector function, but they also restrain tissue injury, cytokine excess, and immune-mediated organ damage. This dual role makes translation fundamentally different from oncology: the goal is not maximal immune activation, but controlled immune recalibration. Evidence is strongest for chronic viral infections and selected oncology-adjacent cohorts, whereas infection-directed trials remain early and heterogeneous. A precision framework based on pathogen burden, immune phenotype, tissue vulnerability, biomarker feasibility, safety monitoring, and implementation context is therefore essential before ICIs can be responsibly developed as host-directed therapies for infectious diseases. This review synthesizes the rationale, evidence, and safety considerations for ICIs in infectious diseases. We discuss chronic viral infections, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Epstein-Barr virus (EBV), and highlight EBV as a bridge between persistent viral infection, immune surveillance, lymphoproliferation, and cancer immunotherapy. We also examine tuberculosis, sepsis, fungal infections, and parasitic diseases, where checkpoint pathways may restore host defense or amplify immunopathology. Finally, we propose a precision-immunotherapy framework integrating pathogen biology, immune phenotype, tissue risk, biomarker feasibility, access, and trial design.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1894437","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:41:08Z","timestamp":1785822068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xvrong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingluan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Sci-Tech Inno Center for Infection & Immunity","place":["Shanghai, China"]},{"name":"Key Laboratory of Medical Molecular Virology (MOE\/MOH), Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13388","article-title":"Immune checkpoint inhibitors in infectious disease","volume":"328","author":"King","year":"2024","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163633","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061800","article-title":"Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade","volume":"203","author":"Freeman","year":"2006","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/d41573-022-00185-0","article-title":"Second CTLA-4-targeted checkpoint inhibitor secures FDA approval","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA-4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr3930","article-title":"Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infection","volume":"17","author":"Li","year":"2025","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg3868","article-title":"Cellular and molecular waypoints along the path of T cell exhaustion","volume":"8","author":"Lan","year":"2023","journal-title":"Sci Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.08.004","article-title":"Checkpoint inhibition and infectious diseases: a good thing","volume":"25","author":"Abers","year":"2019","journal-title":"Trends Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01395-9","article-title":"Tissue adaptation and clonal segregation of human memory T cells in barrier sites","volume":"24","author":"Poon","year":"2023","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01338-4","article-title":"Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics","volume":"23","author":"Giles","year":"2022","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090222-102834","article-title":"T follicular helper cell heterogeneity","volume":"42","author":"Song","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1536020","article-title":"Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2025.2454045","article-title":"Emerging roles of checkpoint molecules on B cells","volume":"48","author":"Asashima","year":"2025","journal-title":"Immunol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000910","article-title":"Monocytes across life span in HIV infection: lights and shadows","volume":"20","author":"Neri","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.03.003","article-title":"Stromal cells and immune cells involved in formation of lymph nodes and their niches","volume":"64","author":"Koning","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s42003-025-08443-8","article-title":"Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma","volume":"8","author":"Liu","year":"2025","journal-title":"Commun Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuae006","article-title":"Evolution and emergence of Mycobacterium tuberculosis","volume":"48","author":"Orgeur","year":"2024","journal-title":"FEMS Microbiol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70501","article-title":"EBV latency programs: molecular and epigenetic regulation and its role in disease pathogenesis","volume":"97","author":"Lyu","year":"2025","journal-title":"J Med Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PloS Pathog"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad149","article-title":"VISTA nonredundantly regulates proliferation and CD69low gamma-delta T cell accumulation in the intestine in murine sepsis","volume":"115","author":"Gray","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00556-2","article-title":"BTLA biology in cancer: from bench discoveries to clinical potentials","volume":"12","author":"Andrzejczak","year":"2024","journal-title":"biomark Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43556-025-00345-9","article-title":"CD39 and CD73: biological functions, diseases and therapy","volume":"6","author":"Shen","year":"2025","journal-title":"Mol BioMed"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRPalpha axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14020138","article-title":"Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine","volume":"14","author":"van Heuvel","year":"2022","journal-title":"Toxins (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112809","article-title":"Immune checkpoint molecules and glucose metabolism in HIV-induced T cell exhaustion","volume":"10","author":"Chan","year":"2022","journal-title":"Biomedicines"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer: A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: A systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04139-y","article-title":"Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy","volume":"32","author":"Talla","year":"2026","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13798","article-title":"Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection","volume":"52","author":"Hagiwara","year":"2022","journal-title":"Hepatol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000438","article-title":"Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients","volume":"78","author":"Genshaft","year":"2023","journal-title":"Hepatology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325915","article-title":"Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/v10110645","article-title":"HCV-specific T cell responses during and after chronic HCV infection","volume":"10","author":"Luxenburger","year":"2018","journal-title":"Viruses"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41467-019-09212-y","article-title":"NKG2A is a NK cell exhaustion checkpoint for HCV persistence","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70007","article-title":"High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam","volume":"12","author":"Vo","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1038\/s41467-022-32283-3","article-title":"A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","article-title":"Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","article-title":"Dynamic single-cell mapping unveils Epstein\u2013Barr virus-imprinted T-cell exhaustion and on-treatment response","volume":"8","author":"Qiu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018748","article-title":"EBV: The virus that keeps on giving","volume":"141","author":"Cairo","year":"2023","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301980RR","article-title":"The novel immune landscape of immune-checkpoint blockade in EBV-associated Malignancies","volume":"38","author":"Zhang","year":"2024","journal-title":"FASEB J"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1451977","article-title":"Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: A systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1323797","article-title":"The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1064346","article-title":"Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and\/or CTLA-4","volume":"14","author":"Fisher","year":"2023","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-023-01128-6","article-title":"Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"12","author":"Liu","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093719","article-title":"Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.7150\/jca.87335","article-title":"The safety of immunosuppressants used in the treatment of immune-related adverse events due to immune checkpoint inhibitors: A systematic review","volume":"14","author":"MaChado","year":"2023","journal-title":"J Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00760-x","article-title":"Mitochondrial control of inflammation","volume":"23","author":"Marchi","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1029438","article-title":"Role of regulation of PD-1 and PD-L1 expression in sepsis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via Jak2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated Malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250le","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo Clinic Phase 2 Consortium","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01867","article-title":"Chronic active Epstein-Barr virus disease","volume":"8","author":"Kimura","year":"2017","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03660-5","article-title":"Updated guidelines for chronic active Epstein-Barr virus disease","volume":"118","author":"Kawada","year":"2023","journal-title":"Int J Hematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: Prospective analysis of 108 cases","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s441460","article-title":"PD-1 blockade-induced hemophagocytic lymphohistiocytosis, a dilemma therapeutic outcome in 2 patients with Caebv: A case series","volume":"17","author":"Chen","year":"2024","journal-title":"Infection Drug Resistance"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1395","article-title":"A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: Does Goldilocks have the answer","volume":"16","author":"Vaddi","year":"2024","journal-title":"J Thorac Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70415","article-title":"High-risk Hpv oncoproteins and PD-1\/PD-L1 interplay","volume":"97","author":"Zhen","year":"2025","journal-title":"J Med Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106158","article-title":"Integrated single-cell transcriptome and T cell receptor profiling reveals defects of T cell exhaustion in pulmonary tuberculosis","volume":"88","author":"Wen","year":"2024","journal-title":"J Infect"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.116","article-title":"Programmed death (PD)-1:PD-ligand 1\/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis","volume":"181","author":"Jurado","year":"2008","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"Lazar-Molnar","year":"2010","journal-title":"PNAS"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.1038\/s41467-025-61826-7","article-title":"Macrophage-T cell interactions promote Slamf1 expression for enhanced TB defense","volume":"16","author":"Krishna Prasad","year":"2025","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf3861","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Sci Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427559","article-title":"Understanding the development of tuberculous granulomas: Insights into host protection and pathogenesis, a review in humans and animals","volume":"15","author":"Lyu","year":"2024","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41581-025-01004-6","article-title":"The immunology of sepsis: Translating new insights into clinical practice","volume":"22","author":"Kox","year":"2026","journal-title":"Nat Rev Nephrol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24175","article-title":"Precision immunotherapy to improve sepsis outcomes: The Immunosep randomized clinical trial","volume":"335","author":"Giamarellos-Bourboulis","year":"2026","journal-title":"JAMA"},{"key":"B104","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40779-022-00422-y","article-title":"Sepsis-induced immunosuppression: Mechanisms, diagnosis and current treatment options","volume":"9","author":"Liu","year":"2022","journal-title":"Mil Med Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/cc10112","article-title":"Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients","volume":"15","author":"Guignant","year":"2011","journal-title":"Crit Care"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/cc13176","article-title":"Targeting the programmed cell death 1: Programmed cell death ligand 1 pathway reverses T-cell exhaustion in patients with sepsis","volume":"18","author":"Chang","year":"2014","journal-title":"Crit Care"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: A phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody Bms-936559","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03956-5","article-title":"A consensus immune dysregulation framework for sepsis and critical illnesses","volume":"31","author":"Moore","year":"2025","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106599","article-title":"Pentraxin-3, Myd88, Glp-1, and PD-L1: Performance assessment and composite algorithmic analysis for sepsis identification","volume":"91","author":"Bauer","year":"2025","journal-title":"J Infect"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.702125","article-title":"Revisiting the mechanisms of immune evasion employed by human parasites","volume":"11","author":"Chulanetra","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2012","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.11.002","article-title":"PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria","volume":"5","author":"Horne-Debets","year":"2013","journal-title":"Cell Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202438","article-title":"Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion","volume":"190","author":"Illingworth","year":"2013","journal-title":"J Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis304","article-title":"PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic Toxoplasma infection","volume":"206","author":"Bhadra","year":"2012","journal-title":"J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13912","article-title":"Cytotoxic signature and IFN-gamma production dominate CD4+ T-cell response during human toxoplasmosis","volume":"175","author":"Henriques","year":"2025","journal-title":"Immunology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674078","article-title":"T cell specificity: A great challenge in Chagas disease","volume":"12","author":"Ferragut","year":"2021","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03537-23","article-title":"Step-by-step: The CD8 T cell journey in leishmaniasis","volume":"16","author":"Fowler","year":"2025","journal-title":"mBio"},{"key":"B120","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/s1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900522","article-title":"Case report: Immune checkpoint blockade plus interferon-gamma add-on antifungal therapy in the treatment of refractory COVID-associated pulmonary aspergillosis and cerebral mucormycosis","volume":"13","author":"Serris","year":"2022","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International (Catch-It) Consortium","volume":"41","author":"El Zarif","year":"2023","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009728","article-title":"Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: Insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study","volume":"12","author":"Assoumou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1499663","article-title":"Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2600158","article-title":"Emergence, function, and therapeutic strategies to target the PD-1\/PD-L1 immune checkpoint during pathogenic fungal infections","volume":"16","author":"Zheng","year":"2025","journal-title":"Virulence"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1807408","article-title":"Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: The infection-immunity-cancer crosstalk","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.790276","article-title":"HIV-1 induction of tolerogenic dendritic cells is mediated by cellular interaction with suppressive T cells","volume":"13","author":"Svanberg","year":"2022","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1530","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium 095 study","volume":"73","author":"Rasmussen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100766","article-title":"Memory CD4+ T cells that co-express PD-1 and CTLA-4 have reduced response to activating stimuli facilitating HIV latency","volume":"3","author":"Rasmussen","year":"2022","journal-title":"Cell Rep Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491330","article-title":"The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hu","year":"2024","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: Mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70367","article-title":"Comparative risk of hepatitis B virus reactivation in patients receiving immune checkpoint inhibitors or tyrosine kinase inhibitors for liver cancer","volume":"63","author":"Yiu","year":"2025","journal-title":"Alimentary Pharmacol Ther"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656063","article-title":"Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.36401\/jipo-23-28","article-title":"Management of hepatitis B virus and hepatitis C virus infections in patients with cancer receiving immune checkpoint inhibitors","volume":"7","author":"Mustafayev","year":"2024","journal-title":"J Immunotherapy Precis Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.02.002","article-title":"Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections","volume":"62","author":"Fujita","year":"2024","journal-title":"Respir Invest"},{"key":"B136","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s40001-025-02694-1","article-title":"The PD-1\/PD-L1 pathway and Epstein-Barr virus","volume":"30","author":"Wang","year":"2025","journal-title":"Eur J Med Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01181-y","article-title":"Epstein-Barr virus pathogenesis and emerging control strategies","volume":"23","author":"M\u00fcnz","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391395","article-title":"Immunotherapy in the context of sepsis-induced immunological dysregulation","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13054-024-04964-6","article-title":"Towards personalized medicine: A scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit Care"},{"key":"B140","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41698-024-00601-1","article-title":"Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma","volume":"8","author":"Liu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01041-5","article-title":"The impact of Plasmodium-driven immunoregulatory networks on immunity to malaria","volume":"24","author":"Boyle","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00345-24","article-title":"Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection","volume":"92","author":"Dookie","year":"2024","journal-title":"Infect Immun"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07499-6","article-title":"Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor","volume":"630","author":"Li","year":"2024","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8+ T cell exhaustion","volume":"26","author":"Sun","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: An update","volume":"12","author":"Naidoo","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update","volume":"39","author":"Brahmer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13313","article-title":"Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections","volume":"11","author":"Xu","year":"2020","journal-title":"Thorac Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3721","article-title":"Comedications associated with immune-related adverse events from immune-checkpoint inhibitors","volume":"118","author":"Laurent","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011636","article-title":"Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC","volume":"13","author":"Kim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8+ T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B156","article-title":"HIV cure-related research: Where we stand and where we go","volume":"47","author":"Ranzenigo","year":"2024","journal-title":"New Microbiol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105248","article-title":"Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses","volume":"221","author":"Petrelli","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B159","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010201","article-title":"Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: Implications for immunotherapy","volume":"12","author":"McMiller","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032277","article-title":"Chronic active Epstein-Barr virus disease: Molecular pathogenesis, evolving concepts, and emerging therapies","volume":"147","author":"Kimura","year":"2026","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100817","article-title":"Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial","volume":"3","author":"Leventogiannis","year":"2022","journal-title":"Cell Rep Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02844-06","article-title":"Characterization of hepatitis B virus-specific T-cell dysfunction in chronic hepatitis B infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1097\/shk.0000000000001443","article-title":"Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: A multicenter, open-label phase 1\/2 study","volume":"53","author":"Watanabe","year":"2020","journal-title":"Shock"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1894437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:41:10Z","timestamp":1785822070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1894437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":167,"alternative-id":["10.3389\/fimmu.2026.1894437"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1894437","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1894437"}}